{"news_desk": "SundayBusiness", "print_page": "12", "section_name": "Business Day", "subsection_name": "Mutual Funds", "byline": {"original": "By JOHN SCHWARTZ", "person": [{"rank": 1, "role": "reported", "firstname": "John", "organization": "", "lastname": "SCHWARTZ"}]}, "abstract": "John Schwartz essay humorously observes Turing Pharmaceuticals founder Martin Shkreli, who bought drug Daraprim and jacked its price to $750 a pill, from $13.50, is using variant on surge pricing; says it shows 32-year-old has chutzpah to go to the top, and asks him to run for president when he turns 35.", "type_of_material": "News", "word_count": "1037", "lead_paragraph": "Martin Shkreli drew criticism for raising the price of the drug Daraprim to $750 a pill from $13.50, but the move suggests he has enough chutzpah to be president.", "pub_date": "2015-10-11T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Take Surge Pricing to the Limit. Then Go Further.", "content_kicker": "Essay", "print_headline": "Take Prices to the Limit. Then Keep Going.", "kicker": "Essay"}, "snippet": "Martin Shkreli drew criticism for raising the price of the drug Daraprim to $750 a pill from $13.50, but the move suggests he has enough chutzpah to be president.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/10/11/business/mutfund/take-surge-pricing-to-the-limit-then-go-further.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Shkreli, Martin (1983- )", "name": "persons"}, {"rank": "3", "is_major": "Y", "value": "Turing Pharmaceuticals AG", "name": "organizations"}, {"rank": "4", "is_major": "N", "value": "Presidential Election of 2016", "name": "subject"}], "blog": [], "_id": "5617fa2638f0d814e137028a", "source": "The New York Times"}